Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab immunomonitoring in autoimmune bullous diseases
NL-OMON51059Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in pemphigus, Bullous Pemphigoid (BP), cicatricial pemphigoid (CP) and 1 more, sponsored by University Medical Center Groningen. Primary endpoints: B-cell phenotype and B-cell repertoire. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
pemphigusBullous Pemphigoid (BP)cicatricial pemphigoid (CP)Immunobullous disease (IBD)
Beyond the preview
Go deeper on NL-OMON51059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51059.